Discover the emerging class of degrader-antibody conjugates – a modality that is drawing increasing interest from biotech ...

Promatix Biosciences, which was founded in 2020, says the scarcity of truly tumour-selective targets is putting the brakes on ...

Conjugation of universal, functionally de-targeted OneAAVTM capsid provides on-demand specificity and scalabilityto address ...

Joining us today is Panna Sharma, Chief Executive Officer, President and Director of Lantern Pharma, who will guide us through the demonstration and discuss the broader implications of this technology ...

This stadium is destined to close without radical intervention. The City Football Group represents a wealth of expertise: ...

Here's today's Connections answer and hints for groups. These clues will help you solve New York Times' popular puzzle game, ...

Company Will Discuss Data and Report First Quarter 2026 Financial Results on May 8 - SOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE ...